A reduction in serum Ig levels was observed over the OLE in ocrelizumab-treated patients, and the proportion of MS patients showing levels below the lower limit of normalranged from 5% for IgG and IgA to 30% for IgM (70, 71). Here, CD40LG is linked to myeloid sarcoma.